scholarly journals Quantum dot-based immunofluorescent imaging of Ki67 and identification of prognostic value in HER2-positive (non-luminal) breast cancer

2014 ◽  
pp. 1339 ◽  
Author(s):  
Sheng-Rong Sun ◽  
Jin-Zhong Sun ◽  
Chuang Chen ◽  
Guan Jiang ◽  
Yan Li ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quantum Dot ◽  
Prognostic Value ◽  
Luminal Breast Cancer ◽  
Her2 Positive

scholarly journals Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer

2011 ◽  
Vol 17 (2) ◽  
pp. 96-104 ◽  
Author(s):  
Naoki Hayashi ◽  
Seigo Nakamura ◽  
Yasuharu Tokuda ◽  
Yuji Shimoda ◽  
Hiroshi Yagata ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Prognostic Value ◽  
Metastatic Breast ◽  
Her2 Positive

scholarly journals Expression Pattern and Prognostic Value of EPHA/EFNA in Breast Cancer by Bioinformatics Analysis: Revealing Its Importance in Chemotherapy

2021 ◽  
Vol 2021 ◽  
pp. 1-20
Author(s):  
Zheng Liang ◽  
Xu Wang ◽  
Kaiti Dong ◽  
Xinhua Li ◽  
Chenge Qin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Mrna Expression ◽  
Expression Pattern ◽  
Prognostic Value ◽  
Genetic Alterations ◽  
Clinicopathological Parameters ◽  
Breast Cancers ◽  
Luminal A ◽  
Her2 Positive ◽  
Poor Overall Survival

The activities of the ephrin family in breast cancer (BrCa) are complex. Family A receptors (EPHA) and ligands (EFNA) can act as oncogenes or tumor suppressors and are implicated in chemoresistance. Here, we examined the expression pattern and prognostic value of the EPHA/EFNA family in patients with breast cancer, including patients with different subtypes or different chemotherapy cohorts. In the UALCAN database, the mRNA expression of EPHA1, EPHA10, EFNA1, EFNA3, and EFNA4 was significantly higher, whereas that of EPHA2, EPHA4, EPHA5, and EFNA5 was significantly lower in breast cancer tissues than in paracancerous tissues. The transcriptional levels of EPHA/EFNA family members were correlated with intrinsic subclasses of breast cancer. The relationship between EPHA/EFNA and the clinicopathological parameters of BrCa was analyzed using bc-GenExMiner V4.5. EPHA1, EPHA2, EPHA4, EPHA7, EFNA3, EFNA4, and EFNA5 were upregulated in estrogen receptor- (ER-) and progesterone receptor- (PR-) negative tumors, whereas EPHA3, EPHA6, and EFNA1 were upregulated in ER- and PR-positive tumors. EPHA1, EPHA2, EFNA3, and EFNA4 mRNA expression was significantly higher in human epidermal growth factor receptor 2- (HER2-) positive tumors than in HER2-negative tumors. Triple-negative status was positively correlated with EPHA1, EPHA2, EPHA4, EPHA7, EFNA3, EFNA4, and EFNA5 and negatively correlated with EPHA3 and EPHA10 mRNA expression. Genetic alterations of EPHA/EFNA in breast cancer varied from 1.1% to 10% for individual genes, as determined by the cBioPortal database. The Kaplan–Meier plotter indicated that high EphA7 mRNA expression was associated with poor overall survival (OS) and recurrence-free survival (RFS), especially in the HER2 and luminal A subtypes. EFNA4 was predicted to have poor OS and RFS in breast cancers, especially in luminal B, basal-like subtype, and patients treated with adjuvant chemotherapy. High EPHA3 expression was significantly associated with better OS and RFS, especially in the luminal A subtype, but with poor RFS in BrCa patients receiving chemotherapy. Our findings systematically elucidate the expression pattern and prognostic value of the EPHA/EFNA family in BrCa, which might provide potential prognostic factors and novel targets in BrCa patients, including those with different subtypes or treated with chemotherapy.

scholarly journals Identification of the Upregulation of MRPL13 as a Novel Prognostic Marker Associated with Overall Survival Time and Immunotherapy Response in Breast Cancer

2021 ◽  
Vol 2021 ◽  
pp. 1-14
Author(s):  
Hongshan Ye ◽  
Ning Zhang
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Survival Time ◽  
Prognostic Value ◽  
Expression Level ◽  
Occurrence Rate ◽  
Her2 Positive ◽  
Overall Survival Time ◽  
Human Cancers ◽  
Pan Cancer

Mitochondrial ribosomal protein (MRPL) genes have been reported to participate in many cellular processes, such as cell proliferation, apoptosis, and cell cycle. Meanwhile, the occurrence rate of breast cancer (BRCA) in China steadily increased. Exploring the prognostic value of MRPL genes in BRCA could provide novel biomarkers for BRCA. In this study, to identify prognosis-related genes in breast cancer, the P value and the hazard ratio (HR) of all genes are analyzed with TCGA database. We revealed higher expression level of CEL, PGK1, WNT3A, USP41, LINC02037, PCMT1, LRP11, MCTS1, TCP1, TMEM31, STK4-AS1, STXBP5, LOC100287036, SLC16A2, MRPL13, DERL1, and TARS was correlated to shorter OS time in BRCA. However, higher expression level of JCHAIN, KLRB1, and TNFRSF14 was correlated to longer OS time in BRCA. The further analysis demonstrated MRPL13 was overexpressed in BRCA. Subtype analysis showed that MRPL13 was overexpressed in luminal, HER2-positive BRCA, and TNBC samples and was highest in TNBC samples. Moreover, we revealed higher expression of MRPL13 was significantly correlated to shorter OS time and higher TMB levels in BRCA. Pan-cancer analysis further revealed the prognostic value of MRPL13 in human cancers. MRPL13 expression was significantly increased in multiple human cancers, such as bladder cancer, colon cancer, liver cancer, and prostate cancer. Pan-cancer TMB and overall survival time showed dysregulation of MRPL13 is significantly related to the OS and TMB levels in various cancers. These results further proved that MRPL13 may be a pan-cancer biomarker for predicting prognosis and the response to immunotherapy.

scholarly journals Graphene quantum dot-based theranostic agents for active targeting of breast cancer

RSC Advances ◽  
2017 ◽  
Vol 7 (19) ◽  
pp. 11420-11427 ◽  
Author(s):  
N. R. Ko ◽  
M. Nafiujjaman ◽  
J. S. Lee ◽  
H.-N. Lim ◽  
Y.-k. Lee ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quantum Dot ◽  
Active Targeting ◽  
Her2 Positive ◽  
Graphene Quantum Dot ◽  
Her2 Positive Breast Cancer ◽  
Theranostic Agent ◽  
Theranostic Agents ◽  
Positive Breast Cancer

A novel GQD-complex was designed as a promising theranostic agent for the treatment of HER2-positive breast cancer.

Sign in / Sign up

Export Citation Format

Share Document